<DOC>
	<DOCNO>NCT02582047</DOCNO>
	<brief_summary>Previous study demonstrate immunogenicity safety co-administration trivalent inactivate influenza vaccine ( IIV3 ) polysaccharide pneumococcal vaccine ( PPV ) pneumococcal conjugate vaccine ( PCV ) . However , direct comparison study evaluate immunogenicity safety IIV3 give concomitantly PCV13 PPV23 elderly . This study intend compare immunogenicity safety concomitant administration elderly subject .</brief_summary>
	<brief_title>Influenza Vaccine Pneumococcal Vaccine</brief_title>
	<detailed_description>During influenza vaccination period , 224 healthy elderly volunteer randomly receive IIV3 give concomitantly either PCV13 ( PCV13+IIV3 ) PPV23 ( PPV23+IIV3 ) 1:1 ratio . Serum hemagglutination-inhibiting ( HI ) antibodies IIV3 measure time vaccination 1 month vaccination . Adverse event record prospectively clinical diary 7-day period .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Adults age ≥65 year sign informed consent Previous pneumococcal vaccine recipient Egg allergy History serious adverse event vaccination Any acute disease infection History neurological symptom sign Impairment immune function immunosuppressant use Bleeding diathesis Fever ( define axillary temperature ³38.0°C ) within 3 day History Streptococcal pneumoniae infection within previous 5 year</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>influenza vaccine</keyword>
	<keyword>pneumococcal vaccine</keyword>
	<keyword>simultaneous vaccination</keyword>
</DOC>